Skip to main content
Top
Published in: Diabetology International 1/2024

08-01-2024 | Insulins | Report of the Committee

New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes in Japan Diabetes Society (English version)

Authors: Akira Shimada, Eiji Kawasaki, Norio Abiru, Takuya Awata, Yoichi Oikawa, Haruhiko Osawa, Hiroshi Kajio, Junji Kozawa, Kazuma Takahashi, Daisuke Chujo, Shinsuke Noso, Tomoyasu Fukui, Junnosuke Miura, Kazuki Yasuda, Hisafumi Yasuda, Akihisa Imagawa, Hiroshi Ikegami

Published in: Diabetology International | Issue 1/2024

Login to get access

Abstract

The diagnostic criteria for slowly progressive type 1 diabetes (slowly progressive insulin-dependent diabetes mellitus; SPIDDM) have been revised by the Committee on Type 1 Diabetes of the Japan Diabetes Society. All of the following three criteria must be met for “a definitive diagnosis of SPIDDM”: (1) presence of anti-islet autoantibodies at some point in time during the disease course; (2) absence of ketosis or ketoacidosis at the diagnosis of diabetes with no requirement of insulin treatment to correct hyperglycemia immediately after diagnosis in principle; and (3) gradual decrease of insulin secretion over time, with insulin treatment required at more than 3 months after diagnosis, and presence of severe endogenous insulin deficiency (fasting serum C-peptide immunoreactivity < 0.6 ng/mL) at the last observed point in time. When a patient fulfills the only (1) and (2), but not (3), he/she is diagnosed with “SPIDDM (probable)” because the diabetes is non-insulin-dependent state.
Literature
1.
go back to reference Kobayashi T, Tamemoto K, Nakanishi K, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care. 1993;16:780–8.CrossRefPubMed Kobayashi T, Tamemoto K, Nakanishi K, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care. 1993;16:780–8.CrossRefPubMed
2.
go back to reference Tanaka S, Ohmori M, Awata T, et al. Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): report by the Committee on Slowly Progressive Insulin-Dependent (type 1) diabetes mellitus of the Japan Diabetes Society. Diabetol Int. 2015;6:1–7.CrossRef Tanaka S, Ohmori M, Awata T, et al. Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): report by the Committee on Slowly Progressive Insulin-Dependent (type 1) diabetes mellitus of the Japan Diabetes Society. Diabetol Int. 2015;6:1–7.CrossRef
3.
go back to reference Urakami T, Suzuki J, Yoshida A, et al. Incidence of children with slowly progressive form of type 1 diabetes detected by the urine glucose screening at schools in the Tokyo Metropolitan Area. Diabetes Res Clin Pract. 2008;80:473–6.CrossRefPubMed Urakami T, Suzuki J, Yoshida A, et al. Incidence of children with slowly progressive form of type 1 diabetes detected by the urine glucose screening at schools in the Tokyo Metropolitan Area. Diabetes Res Clin Pract. 2008;80:473–6.CrossRefPubMed
4.
go back to reference Rajkumar V, Levine SN. Latent autoimmune diabetes. In: StatPearls. Treasure Island: StatPearls Publishing; 2022. Rajkumar V, Levine SN. Latent autoimmune diabetes. In: StatPearls. Treasure Island: StatPearls Publishing; 2022.
5.
go back to reference Zachariah S, Sharfi MO, Nussey SS, et al. Latent autoimmune diabetes in the young. Clin Med (Lond). 2008;8:552–3.CrossRefPubMed Zachariah S, Sharfi MO, Nussey SS, et al. Latent autoimmune diabetes in the young. Clin Med (Lond). 2008;8:552–3.CrossRefPubMed
6.
go back to reference Kawasaki E, Maruyama T, Imagawa A, Diagnostic criteria for acute-onset type 1 diabetes mellitus, et al. Report of the Committee of Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus. Diabetol Int. 2012;2013(4):221–5.CrossRef Kawasaki E, Maruyama T, Imagawa A, Diagnostic criteria for acute-onset type 1 diabetes mellitus, et al. Report of the Committee of Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus. Diabetol Int. 2012;2013(4):221–5.CrossRef
7.
go back to reference Maruyama T, Tanaka S, Shimada A, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetesmellitus. J Clin Endocrinol Metab. 2008;93:2115–21.CrossRefPubMed Maruyama T, Tanaka S, Shimada A, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetesmellitus. J Clin Endocrinol Metab. 2008;93:2115–21.CrossRefPubMed
8.
go back to reference Nishimura A, Matsumura K, Kikuno S, et al. Slowly progressive type 1 diabetes mellitus: current knowledge and future perspectives. Diabetes Metab Syndr Obes. 2019;12:2461–77.CrossRefPubMedCentralPubMed Nishimura A, Matsumura K, Kikuno S, et al. Slowly progressive type 1 diabetes mellitus: current knowledge and future perspectives. Diabetes Metab Syndr Obes. 2019;12:2461–77.CrossRefPubMedCentralPubMed
9.
go back to reference Yasui J, Kawasaki E, Tanaka S, et al. Clinical and genetic characteristics of non-insulin-requiring glutamic acid decarboxylase (GAD) autoantibody-positive diabetes: a nationwide survey in Japan. PLoS ONE. 2016;11:e0155643.CrossRefPubMedCentralPubMed Yasui J, Kawasaki E, Tanaka S, et al. Clinical and genetic characteristics of non-insulin-requiring glutamic acid decarboxylase (GAD) autoantibody-positive diabetes: a nationwide survey in Japan. PLoS ONE. 2016;11:e0155643.CrossRefPubMedCentralPubMed
10.
go back to reference Awata T, Shimada A, Maruyama T, et al. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial (SPAN-S). Diabetes Ther. 2017;8:1123–34.CrossRefPubMedCentralPubMed Awata T, Shimada A, Maruyama T, et al. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial (SPAN-S). Diabetes Ther. 2017;8:1123–34.CrossRefPubMedCentralPubMed
11.
go back to reference Redondo MJ, Morgan NG. Heterogeneity and endotypes in type 1 diabetes mellitus. Nat Rev Endocrinol. 2023;19:542–54.CrossRefPubMed Redondo MJ, Morgan NG. Heterogeneity and endotypes in type 1 diabetes mellitus. Nat Rev Endocrinol. 2023;19:542–54.CrossRefPubMed
12.
go back to reference Buzzetti R, Tuomi T, Mauricio D, et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes. 2020;69:2037–47.CrossRefPubMedCentralPubMed Buzzetti R, Tuomi T, Mauricio D, et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes. 2020;69:2037–47.CrossRefPubMedCentralPubMed
13.
go back to reference Shimada A, Kawasaki E, Abiru N, et al. Diagnostic criteria of SPIDDM (2023). J Japan Diabetes Soc. 2023;66:587–91 (In Japanese). Shimada A, Kawasaki E, Abiru N, et al. Diagnostic criteria of SPIDDM (2023). J Japan Diabetes Soc. 2023;66:587–91 (In Japanese).
Metadata
Title
New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes in Japan Diabetes Society (English version)
Authors
Akira Shimada
Eiji Kawasaki
Norio Abiru
Takuya Awata
Yoichi Oikawa
Haruhiko Osawa
Hiroshi Kajio
Junji Kozawa
Kazuma Takahashi
Daisuke Chujo
Shinsuke Noso
Tomoyasu Fukui
Junnosuke Miura
Kazuki Yasuda
Hisafumi Yasuda
Akihisa Imagawa
Hiroshi Ikegami
Publication date
08-01-2024
Publisher
Springer Nature Singapore
Published in
Diabetology International / Issue 1/2024
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-023-00679-1

Other articles of this Issue 1/2024

Diabetology International 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.